Fenfluramine: a review in Dravet and Lennox-gastaut syndromes
JE Frampton - Drugs, 2023 - Springer
Fenfluramine (Fintepla®) is an oral anti-seizure medication (ASM) with a novel mechanism
of action consisting of activity in the serotonergic system coupled with positive allosteric …
of action consisting of activity in the serotonergic system coupled with positive allosteric …
Serotonin receptors in epilepsy: Novel treatment targets?
J Sourbron, L Lagae - Epilepsia Open, 2022 - Wiley Online Library
Despite the availability of over 30 antiseizure medications (ASMs), there is no “one size fits it
all,” so there is a continuing search for novel ASMs. There are divergent data demonstrating …
all,” so there is a continuing search for novel ASMs. There are divergent data demonstrating …
Efficacy and safety of dietary therapies for childhood drug-resistant epilepsy: a systematic review and network meta-analysis
Importance Despite advances in the understanding of dietary therapies in children with drug-
resistant epilepsy, no quantitative comparison exists between different dietary interventions …
resistant epilepsy, no quantitative comparison exists between different dietary interventions …
Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis
J Wu, L Zhang, X Zhou, J Wang, X Zheng… - Frontiers in …, 2022 - frontiersin.org
Purpose: Recently, the US Food and Drug Administration (FDA) approved stiripentol,
cannabidiol, and fenfluramine to treat patients with Dravet syndrome (DS). Moreover …
cannabidiol, and fenfluramine to treat patients with Dravet syndrome (DS). Moreover …
Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox–Gastaut syndrome in clinical practice
EC Wirrell, L Lagae, IE Scheffer, JH Cross… - Epilepsia …, 2024 - Wiley Online Library
Fenfluramine (FFA), an antiseizure medication (ASM) with serotonergic and sigma‐1
receptor activity, is used to manage patients with developmental and epileptic …
receptor activity, is used to manage patients with developmental and epileptic …
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis
R Guerrini, C Chiron, D Vandame, W Linley… - Epilepsia …, 2024 - Wiley Online Library
Objectives Stiripentol, fenfluramine, and cannabidiol are licensed add‐on therapies to treat
seizures in Dravet Syndrome (DS). There are no direct or indirect comparisons assessing …
seizures in Dravet Syndrome (DS). There are no direct or indirect comparisons assessing …
[HTML][HTML] Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis
Purpose To assess the short-term and long-term comparative efficacy and safety of ASMs for
Lennox-Gastaut syndrome (LGS). Methods Following a systematic literature search …
Lennox-Gastaut syndrome (LGS). Methods Following a systematic literature search …
Comprehensive scoping review of fenfluramine's role in managing generalized tonic–clonic seizures in developmental and epileptic encephalopathies
A Gil‐Nagel, JH Cross, O Devinsky, B Ceulemans… - …, 2024 - Wiley Online Library
Developmental and epileptic encephalopathies (DEEs) are characterized by
pharmacoresistant seizures and developmental delay. Patients with DEEs experience …
pharmacoresistant seizures and developmental delay. Patients with DEEs experience …
Evaluation of burden of SCN1A pathogenicity in North Indian children with Dravet syndrome
Background Dravet syndrome is an infantile-onset developmental and epileptic
encephalopathy with limited data on the frequency of SCN1A in Indian children. The study …
encephalopathy with limited data on the frequency of SCN1A in Indian children. The study …
Update on cannabidiol in drug-resistant epilepsy
Cannabidiol (CBD) has arisen as a promising therapeutic option for children with drug-
resistant epilepsy (DRE). CBD has received regulatory nod from different regulatory …
resistant epilepsy (DRE). CBD has received regulatory nod from different regulatory …